Vice President of Finance
John McCabe brings more than 25 years of finance and accounting experience to resTORbio. Prior to joining resTORbio, he was Chief Financial Officer with Eleven Biotherapeutics, Inc., a biologics oncology company focused on the development of novel therapies based upon tumor targeting antibody fragments genetically fused to a cytotoxic protein payload called Targeted Protein Therapeutics (TPTs).
Prior to that, Mr. McCabe served as Vice President of Finance at Clinical Data, Inc., a drug developer that was acquired by Forest Laboratories for $1.2 billion after FDA approval of its lead drug product for depression, Viibryd®. Prior to that, Mr. McCabe served in several financial roles at Interleukin Genetics, Inc., a genetics-focused personalized health company. John began his career working for the accounting firm of Coopers & Lybrand LLP, now known as PricewaterhouseCoopers LLP. He received a B.S. in Business Administration from the University of Vermont and is also a Certified Public Accountant.